Polygenic Risk Scores Validated in Patient-Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease.

Giuseppe ArenaZied LandoulsiDajana GrossmannThomas PayneArmelle VitaliSylvie DelcambreAlexandre BaronPaul M A AntonyIbrahim BoussaadDheeraj Reddy BobbiliAshwin Ashok Kumar SreelathaLukas PavelkaNico J DiederichChristine KleinPhilip SeiblerEnrico GlaabThomas FoltynieOliver Bandmann Manu Sharma Rejko Krüger Patrick May Anne Grünewaldnull null

Published in: Annals of neurology (2024)

OXPHOS-PRS may provide a precision medicine tool to stratify iPD patients into a pathogenic subgroup genetically defined by specific mitochondrial impairment, making these individuals eligible for future intelligent clinical trial designs. ANN NEUROL 2024;96:133-149.

Keyphrases

clinical trial
end stage renal disease
oxidative stress
induced apoptosis
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
randomized controlled trial
open label
patient reported outcomes
signaling pathway
current status
patient reported